Metastatic Breast Cancer Clinical Trials
Metastatic Breast Cancer clinical trials evaluate new drugs, immunotherapies, radiation approaches, and combination treatments for metastatic Breast Cancer. Corterve aggregates actively recruiting Metastatic Breast Cancer studies from the public ClinicalTrials.gov registry so you can browse them by location and eligibility. Many oncology trials enroll patients at different stages of disease, including newly diagnosed and previously treated. This is general information, not medical advice — review any study with your oncology care team before enrolling.
Recruiting Metastatic Breast Cancer studies
- Evolutionary Clinical Trial for Novel Biomarker-Driven TherapiesNCT07340541PHASE2UNC Lineberger Comprehensive Cancer CenterNew Haven, Connecticut
- A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast CancerNCT06369285PHASE2Puma Biotechnology, Inc.Birmingham, Alabama
- A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast CancerNCT05894239PHASE3Hoffmann-La RocheGilbert, Arizona
- BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid TumorsNCT06120283PHASE1BeOne MedicinesDenver, Colorado
- A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid TumorsNCT07318805PHASE1PfizerDuarte, California
- Asciminib in HER2+ Breast Cancer Brain MetastasesNCT07136428PHASE1, PHASE2Duke UniversityDurham, North Carolina
- Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast CancerNCT06982521PHASE3Relay Therapeutics, Inc.Gilbert, Arizona
- BettER: Biomarker Driven Early Therapeutic Selection in Patients With HR+ HER2- Metastatic or Unresectable Breast CancerNCT05977036NAWashington University School of MedicineSt Louis, Missouri
- CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast CancerNCT05029999PHASE1University of Texas Southwestern Medical CenterChicago, Illinois
- Study of Palliative Radiation Combined with Pembrolizumab in Unresectable Metastatic Stage IV Breast CancerNCT04990921PHASE2University of LouisvilleLouisville, Kentucky
- Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain MetastasesNCT04923542PHASE1, PHASE2H. Lee Moffitt Cancer Center and Research InstituteTampa, Florida
- Discontinuation of Maintenance HER-2 Directed Therapy in Long-Term Survivors of Metastatic HER-2 Positive Breast CancerNCT05959291NAUniversity of MiamiMiami, Florida
Metastatic Breast Cancer trials by state
Metastatic Breast Cancer trials by metro
Frequently asked questions
- How do I find recruiting Metastatic Breast Cancer clinical trials?
- Corterve aggregates actively recruiting Metastatic Breast Cancer studies from the public ClinicalTrials.gov registry. Browse the studies listed on this page or take a free health assessment to see trials you may qualify for based on your profile.
- Are Metastatic Breast Cancer clinical trials free to join?
- Study participation is typically free — research sponsors cover the cost of the investigational treatment and study-related visits. Many trials also compensate participants for time and travel. Details vary by study.
- Who can take part in a Metastatic Breast Cancer clinical trial?
- Each study has its own eligibility criteria (for example age, disease stage, and prior treatments). This page is general information and not medical advice; discuss any specific trial with your healthcare provider to confirm whether it is appropriate for you.